Intellipharmaceutics International Inc. (IPCI)

[fred198484]

From Mackie's report on the new CFO - it will be interesting to see how he raises cash, new shares are not to only possibility.


Mr. Patient’s experience with Merus should be beneficial to IPCI. We believe his first priorities will be to strengthen the balance sheet and
try to rebuild investor confidence.

Rexista-Oxycodone PDUFA date: On July 26, the FDA advisory committee meeting set the tone for this product and voted in favour of not approving the formulation with its current clinical package. The PDUFA data for IPCI’s Rexista-oxycodone is September 25, 2017 – we are expecting a complete response letter, that is, we do not expect approval at this time. IPCI needs to get out from the shadow of Rexista and refocus its pipeline.
IMPACT – Maintaining HOLD and Target Price We expect IPCI to trade at a discount to its peer Canadian specialty pharmas due to: its current revenues mix being derived from generics (not brand), lack of near term new
product launch visibility, and potential